Signal Report · US
BMY HOLD
Composite decision report grounded in 1-XH strategy signals and multi-agent debate, generated by DeepSeek at 2026-06-29 08:47.
🎯 Final Decision
Action
HOLD
Weight
0%
Confidence
30%
Variant
xiaohan_gogo_v2
Reasons
- Bull case relies heavily on a single proprietary factor (xh_gogo_score) that is double-counted across technical and cross-sectional signals, reducing independent confirmation.
- Bear case highlights weak risk-adjusted returns (sharpe_60d) and lack of fundamental catalyst, but the counter shows these are typical mean-reversion setups.
- Both sides have surviving counters: the bull's pattern could fail in a persistent downtrend, while the bear's exclusion from production basket may be a model artifact.
- Composite z-score of +0.80 is modest, and the technical signal (0.80) is probabilistic, not a guarantee, leading to mixed conviction.
- Regime tilt is bullish but not strong enough to override the balanced arguments; prefer to wait for clearer catalyst or stronger confirmation.
Bull Case (Analyst)
- The technical signal is strongly bullish: a buy action with a score of 0.80 from the xiaohan_gogo_v2 strategy, supported by a rare multi-timeframe bottom formation (1h through daily bottom) and a blue_upper_above_yellow_upper crossover on the 1h chart. This pattern often precedes a mean-reversion rally. - The cross-sectional factor view ranks BMY 5th out of 251 stocks (top 2.0%) with a composite z-score of +0.80 in a BULL regime catalog with zero direction-flips, indicating broad factor alignment for longs. - The top lifter is the xh_gogo_score at +3.00 z, directly corroborating the technical signal — the same proprietary momentum/bottom-detection factor driving the buy call is also the strongest cross-sectional contributor to BMY's rank. - Bollinger b_20d (+1.12 z) and volume_momentum_60d (+1.04 z) are also positive lifters, suggesting the stock is oversold on a volatility-adjusted basis and seeing accumulation over the past 60 days, supporting a reversal narrative.
Bear Case (Analyst)
- The cross-sectional factor view explicitly notes BMY is not in the production basket, meaning despite its high composite rank, the model did not select it for the top decile portfolio — a cautionary signal that the rank may be fragile or driven by a narrow set of factors. - Top draggers include sharpe_60d (-0.67 z) and beta_60d (-0.66 z), indicating poor risk-adjusted returns and low sensitivity to market moves over the past 60 days — problematic for a stock relying on mean-reversion, as it suggests persistent weakness rather than a temporary dip. - The news item is about AbbVie's acquisition of Apogee, not directly about BMY, and carries a neutral/questionable sentiment marker. No positive catalyst or company-specific news supports the technical buy signal, leaving it reliant solely on pattern recognition. - Close_to_high_60d is a slight drag (-0.08 z), confirming the stock is not near recent highs, and the technical "bottom" pattern could simply reflect a downtrend continuation rather than a reversal, especially given the weak momentum and beta factors.
Devil's Advocate
COUNTER TO BULL: - The xiaohan_gogo_v2 strategy score of 0.80 is not a 1.0 — it's a probabilistic signal, not a guarantee. Multi-timeframe bottoms can fail if the trend is strong enough to absorb them; the "rare" pattern may be rare precisely because it's unreliable in weak hands. - Cross-sectional rank of 5th out of 251 sounds impressive, but the composite z-score is only +0.80 — that's barely one standard deviation above mean. In a BULL regime with zero flips, this could be a crowded long that's already priced in, not a fresh opportunity. - The xh_gogo_score being the top lifter at +3.00 z is circular reasoning: the same factor driving the technical signal is also the top factor in the rank. This is double-counting, not independent confirmation. If that factor is wrong, both legs collapse. - Bollinger b_20d at +1.12 z and volume_momentum_60d at +1.04 z are modest oversold signals. Oversold can persist for weeks in a downtrend — accumulation doesn't guarantee reversal, especially if the accumulation is from passive funds rebalancing, not active buying. COUNTER TO BEAR: - "Not in production basket" is a model-specific exclusion, not a fundamental flaw. The model may have a narrow top-decile filter that misses high-rank stocks due to liquidity or sector constraints — BMY's rank could be genuine but just outside an arbitrary cutoff. - Sharpe_60d at -0.67 z and beta_60d at -0.66 z are weak, but mean-reversion trades often thrive on exactly this: a stock that's been beaten down (low sharpe) and is non-correlated (low beta) can snap back hard when sentiment shifts. Weakness is the setup, not the flaw. - The AbbVie/Apogee news is neutral, but lack of catalyst doesn't invalidate a technical pattern. Many reversals happen without news — the pattern itself is the catalyst if enough algos trigger on it. Absence of evidence is not evidence of absence. - Close_to_high_60d at -0.08 z is essentially flat — not a meaningful drag. A stock near its 60-day low is exactly where a bottom pattern should form. Calling it a "downtrend continuation" is a tautology: every bottom looks like a continuation until it isn't.
Technical Signal (1-XH)
action
buy
score
0.80
variant
xiaohan_gogo_v2
timestamp
2026-06-26 15:30:00
close
57.51
ema_low_fast
55.93
ema_high_slow
56.12
gogo_score
0.8
gogo_detail
1h_bottom,2h_bottom,3h_bottom,4h_bottom,1h_blue_upper_above_yellow_upper,daily_bottom
📈 Backtest Track Record xiaohan_gogo_v2 · signals simulated over available history (~3-month 30-min window, accumulating daily)
Trades
1
Win rate
100%
Avg / trade
+3.6%
Total (compounded)
+4%
best / worst
+3.6% / +3.6%
avg holding
3.2 days
open position
yes — marked-to-market +3.6%
| Entry | Exit | Entry | Exit | Return | Exit reason |
|---|---|---|---|---|---|
| 2026-06-23 | open | 55.52 | 57.51 | +3.6% | open_position_mark_to_market |
News & social (1 items)
-
wsj.comAbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJThis copy is for your personal, non-commercial use only. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/deals/abbvie-to-buy-apo…